TICKERNERD
Menu
CELCCELCHealthcare · Biotechnology

CELC Stock Forecast: Celcuity, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$91
−2.93% on the day

The 12 Wall Street analysts covering Celcuity, Inc. hold a median 12-month price target of $163 — +79.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$4.4B
Ticker Nerd rank
30 / 100
Median analyst target
$163
Analysts covering
12
Revenue$0.0
Operating income−$50.5M
Net income−$52.8M
Free cash flow−$55.4M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.8%
1M
+9.9%
YTD
−9.0%
1Y
+73.2%
From 52W high
−37.4%
From 52W low
+100.8%
$45
$145
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CELC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Celcuity, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
88
Momentum
80
Quality
54
Volatility
44
Accruals
38
Revisions
32
Growth
31
Size
25
Issuance
5

Value (88): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CELC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CELC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Oct 25Jan 26Apr 26Jul 26CELCHigh $177Median $163Low $140

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $140Median $163High $177

The green dot is the last close — the median target sits +79.5% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 5 moved it down.

DateFirmActionRatingTarget
17 Aug 2026CitizensReiteratesMarket Outperform$177
17 Aug 2026GuggenheimMaintainsBuy$165 → $175
14 Aug 2026HC Wainwright & Co.ReiteratesBuy$155
14 Aug 2026NeedhamMaintainsBuy$157 → $140
14 Aug 2026StifelMaintainsBuy$175 → $150
15 July 2026CitizensMaintainsMarket Outperform$160 → $177
15 July 2026CitizensMaintainsMarket Outperform—
15 July 2026HC Wainwright & Co.MaintainsBuy—
15 July 2026HC Wainwright & Co.MaintainsBuy$145 → $155
3 June 2026Craig-HallumMaintainsBuy—
3 June 2026Craig-HallumMaintainsBuy$189 → $171
3 June 2026HC Wainwright & Co.MaintainsBuy$185 → $145
3 June 2026HC Wainwright & Co.MaintainsBuy—
3 June 2026Wells FargoMaintainsOverweight—
3 June 2026Wells FargoMaintainsOverweight$183 → $166
18 May 2026HC Wainwright & Co.MaintainsBuy—
15 May 2026NeedhamReiteratesBuy—
15 May 2026Wells FargoMaintainsOverweight—
4 May 2026CitizensMaintainsMarket Outperform—
4 May 2026GuggenheimMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CELC appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CELC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Celcuity, Inc. returned +73.2% against +19.6% for the S&P 500, dividends included.

CELC vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26CELCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CELC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Celcuity, Inc. (CELC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−24.0×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
92.4×

Cheaper than 2% of US stocks

EV / EBITDA
−21.3×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−1433.7%

Higher than 1% of US stocks

Return on assets
−25.8%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Celcuity, Inc. (CELC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Celcuity, Inc. has a market value of $4.4B and an enterprise value of $4.4B.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$192.9M.

  • Diluted earnings per share, trailing twelve months: $−3.90.

  • Free cash flow in the twelve months to 31 Mar 2026: −$173.0M, after $225K of capital spending.

  • Shares outstanding: 48.3M.

  • Trailing P/E: −24.0×; forward P/E: −1134.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Celcuity, Inc. employs 155 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

CELC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CELCCelcuity, Inc.$4.4B
30
PBLSParabilis Medicines, Inc.$4.7B
0
EWTXEdgewise Therapeutics, Inc.$4.7B
51
DYNDyne Therapeutics, Inc.$4.8B
29
ELVNEnliven Therapeutics, Inc.$4.3B
68
MANEVeradermics, Inc.$4.2B
2
ACADACADIA Pharmaceuticals, Inc.$5.0B
82

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Celcuity, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CELC news & analysis

Celcuity: REVTORPYK Is Now A Commercial Story

Seeking Alpha · 14 Aug 2026positive

Celcuity received FDA approval for REVTORPYK (gedatolisib) with rapid NCCN Category 1 inclusion, and VIKTORIA-1 data showing improved efficacy and tolerability. Its financials reflect front-loaded commercial investment with rising SG&A, while a strengthened $754M cash position provides funding visibility into 2029.

Why it matters — A CELC watcher would care because the FDA approval and NCCN Category 1 inclusion de-risk the drug's clinical and commercial adoption, positioning REVTORPYK as a potential blockbuster franchise.

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Benzinga · 14 Aug 2026neutral

Celcuity reported a second-quarter loss that was narrower than expected on Thursday. In response, analysts have cut their forecasts for the company.

Why it matters — Celcuity watchers would care because analysts revising their projections directly affects expectations for the company's financial outlook.

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

Seeking Alpha · 14 Aug 2026neutral

Celcuity Inc. published the transcript of its Q2 2026 earnings call on Seeking Alpha, providing a record of management's discussion of the company's quarterly results.

Why it matters — CELC watchers would review the transcript for management commentary on the company's recent performance and outlook.

Celcuity Q2 Earnings Call Highlights

MarketBeat · 13 Aug 2026positive

Celcuity confirmed it is on track to begin commercial shipments of REVTORPYK (gedatolisib therapy) for certain advanced breast cancer patients in late Q3 2026, following recent FDA approval.

Why it matters — This update signals that Celcuity is moving from the regulatory approval phase toward commercialization of its first product, a key milestone for the company.

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewsWire · 13 Aug 2026neutral

Celcuity Inc., a biotechnology company developing targeted therapies for multiple solid tumor indications, announced its financial results for the second quarter ended June 30, 2026, along with other recent business developments. The announcement was made in a press release dated August 13, 2026.

Why it matters — A CELC watcher would care because this release provides the company's latest financial performance and an update on its business activities and clinical progress.

FAQ

Frequently asked questions about CELC stock

What is the CELC stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Celcuity, Inc. have a median 12-month price target of $163, with estimates ranging from $140 to $177. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CELC stock a buy right now?

Of the 12 analysts covering Celcuity, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Celcuity, Inc. 30 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CELC?

As at 22 Aug 2026, Celcuity, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (88 of 100).

Will CELC stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +79.5% from the last close, and Ticker Nerd's factor model ranks Celcuity, Inc. 30 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CELC stock forecast for 2030?

No analyst covering Celcuity, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CELC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $177 over the next 12 months.

How has CELC stock performed over the past year?

Celcuity, Inc. returned +73.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Celcuity, Inc. do?

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications.

What is the latest news on CELC?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Celcuity: REVTORPYK Is Now A Commercial Story". Celcuity received FDA approval for REVTORPYK (gedatolisib) with rapid NCCN Category 1 inclusion, and VIKTORIA-1 data showing improved efficacy and tolerability. Its financials reflect front-loaded commercial investment with rising SG&A, while a strengthened $754M cash position provides funding visibility into 2029.

Company

About Celcuity, Inc.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for multiple solid tumor indications. The company’s lead product candidate, gedatolisib, is designed to inhibit the PI3K/AKT/mTOR signaling pathway, which plays a central role in cancer cell growth and survival. Celcuity’s current research and development efforts are centered on breast and prostate cancers, with additional work in other tumor types linked to the same pathway. The company also develops the CELsignia companion diagnostic platform, which analyzes live tumor cells to help identify patient groups that may benefit from targeted cancer treatments. Based in Minneapolis, Minnesota, Celcuity operates as a precision oncology company aiming to improve how cellular abnormalities are detected and addressed in cancer care.

CEO Mr. Brian F. Sullivan · 155 employees · United States · https://www.celcuity.com